{"doi":"10.1001/jamaoncol.2019.6152","title":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab","abstract":"Importance: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. Objective: To examine whether T-VEC in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma. Design, Setting, and Participants: This open-label, single-institution phase 2 interventional trial of T-VEC plus pembrolizumab enrolled 20 patients with locally advanced or metastatic sarcoma between March 16 and December 4, 2017, for whom at least 1 standard systemic therapy had failed. The median duration of therapy was 16 weeks (range, 7-67 weeks). Reported analyses include data through December 14, 2018. Intervention: Patients received pembrolizumab (200-mg flat dose) intravenously and T-VEC (first dose, ≤4 mL × 106 plaque-forming units [PFU]/mL; second and subsequent doses, ≤4 mL × 108 PFU/mL) injected into palpable tumor site(s) on day 1 of each 21-day cycle. Main Outcomes and Measures: The primary end point was objective response rate (ORR; complete response and partial response) at 24 weeks determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, criteria. Secondary end points included best ORR by immune-related RECIST criteria, progression-free survival rate at 24 weeks, overall survival, and safety. Results: All 20 patients (12 women [60%]; median age, 63.5 years [range, 24-90 years]) were evaluable for response. The study met its primary end point of evaluating the best ORR at 24 weeks determined by RECIST, version 1.1, criteria; the best ORR was 30% (95% CI, 12%-54%; n = 6). The ORR overall was 35% (95% CI, 15%-59%; n = 7). The incidence of grade 3 treatment-related adverse events was low (4 patients [20%]). There were no grade 4 treatment-related adverse events or treatment-related deaths. Conclusions and Relevance: In this phase 2 clinical trial, treatment with T-VEC plus pembrolizumab was associated with antitumor activity in advanced sarcoma across a range of sarcoma histologic subtypes, with a manageable safety profile. This combination therapy met its predefined primary study end point; further evaluation of T-VEC in combination with pembrolizumab for patients with select sarcoma subtypes is planned. Trial Registration: ClinicalTrials.gov identifier: NCT03069378.","journal":"JAMA Oncology","year":2020,"id":50154,"datarank":5.049146941491626,"base_score":5.337538079701318,"endowment":5.337538079701318,"self_citation_contribution":0.8006307119551977,"citation_network_contribution":4.2485162295364285,"self_endowment_contribution":0.8006307119551977,"citer_contribution":4.2485162295364285,"corpus_percentile":null,"corpus_rank":null,"citation_count":207,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9593,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03069378"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":35289,"name":"Cristina R. Antonescu","orcid":"0000-0002-9717-8205","position":1,"is_corresponding":false},{"id":248387,"name":"Timothy G. Bowler","orcid":null,"position":2,"is_corresponding":false},{"id":245663,"name":"Rodrigo Ramella Munhoz","orcid":"0000-0001-8898-2798","position":3,"is_corresponding":false},{"id":245664,"name":"Ping Chi","orcid":"0000-0002-0159-5531","position":4,"is_corresponding":false},{"id":245665,"name":"Mark A. Dickson","orcid":"0000-0003-2764-751X","position":5,"is_corresponding":false},{"id":90736,"name":"Mrinal M. Gounder","orcid":"0000-0001-8468-0119","position":6,"is_corresponding":false},{"id":245666,"name":"Mary Louise Keohan","orcid":"0000-0002-8240-4900","position":7,"is_corresponding":false},{"id":244420,"name":"Sujana Movva","orcid":"0000-0002-6569-6606","position":8,"is_corresponding":false},{"id":248388,"name":"Reena Dholakia","orcid":null,"position":9,"is_corresponding":false},{"id":248389,"name":"Hamza Ahmad","orcid":null,"position":10,"is_corresponding":false},{"id":245667,"name":"Matthew D. Biniakewitz","orcid":"0009-0009-9731-2337","position":11,"is_corresponding":false},{"id":248390,"name":"Mercedes M. Condy","orcid":null,"position":12,"is_corresponding":false},{"id":248391,"name":"Haley T. Phelan","orcid":null,"position":13,"is_corresponding":false},{"id":68930,"name":"Margaret K. Callahan","orcid":"0000-0002-9087-0012","position":14,"is_corresponding":false},{"id":245668,"name":"Phillip Wong","orcid":"0000-0002-6360-849X","position":15,"is_corresponding":false},{"id":64014,"name":"S. J. Singer","orcid":null,"position":16,"is_corresponding":false},{"id":245669,"name":"Charlotte E. Ariyan","orcid":"0000-0003-0818-3895","position":17,"is_corresponding":false},{"id":245670,"name":"Edmund K. Bartlett","orcid":"0000-0002-0923-153X","position":18,"is_corresponding":false},{"id":245671,"name":"Aimeé M. Crago","orcid":"0000-0002-2965-752X","position":19,"is_corresponding":false},{"id":75231,"name":"Sam S. Yoon","orcid":"0000-0002-5033-6501","position":20,"is_corresponding":false},{"id":245672,"name":"Sinchun Hwang","orcid":"0000-0002-6402-3020","position":21,"is_corresponding":false},{"id":245673,"name":"Joseph P. Erinjeri","orcid":"0000-0003-1876-727X","position":22,"is_corresponding":false},{"id":245674,"name":"Li‐Xuan Qin","orcid":"0000-0002-9367-3807","position":23,"is_corresponding":false},{"id":245675,"name":"William D. Tap","orcid":"0000-0001-7779-2796","position":24,"is_corresponding":false},{"id":245676,"name":"Sandra P. D’Angelo","orcid":"0000-0002-3736-3783","position":25,"is_corresponding":false},{"id":90742,"name":"Ciara M. Kelly","orcid":"0000-0002-4393-8088","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-18T20:38:25.860949Z","pmid":"31971541","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}